Author

Chi-Wei Duann

Observed names: C.-W. Duann, Chi‐Wei Duann

Institution: Eli Lilly (United States)

Observed institutions: Eli Lilly (United States), Taipei Veterans General Hospital, National Yang Ming University

OpenAlex ID: A5077018398

Surgical outcomes in lung cancer presenting as ground-glass opacities of 3 cm or less: A review of 5 years' experience

2013 · Chi-Wei Duann, Jung-Jyh Hung, et al. · Journal of the Chinese Medical Association · 21

Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan

2021 · Kun-Huei Yeh, Tsai-Sheng Yang, et al. · Journal of the Formosan Medical Association · 18

Successful percutaneous tracheostomy via puncture through the thyroid isthmus

2014 · Chi‐Wei Duann, Min‐Shiau Hsieh, et al. · Respirology Case Reports · 7

Real-world evidence of the safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) from Taiwan: A subgroup analysis from the prospective, observational CORRELATE study

2018 · K.-H. Yeh, T.-S. Yang, et al. · Annals of Oncology · 2

BRUIN MCL-321: A phase 3, open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor naïve mantle cell lymphoma.

2023 · Michael Wang, Toby A. Eyre, et al. · Journal of Clinical Oncology · 1

HSR23-101: Characteristics and Outcomes of Patients Treated With Selpercatinib in the Real-World: A Retrospective Study Using US Claims Databases

2023 · Naleen Raj Bhandari, Neha Bansal, et al. · Journal of the National Comprehensive Cancer Network

Works count: 6

Citation count: 49

H-index: 3

I10-index: 2